Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/27/2003WO2003097042A1 Pgd2 receptor antagonist
11/27/2003WO2003097040A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003WO2003097037A1 Allergic symptom reliever
11/27/2003WO2003097034A1 TGF-α EXPRESSION INHIBITORS
11/27/2003WO2003097031A1 Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient
11/27/2003WO2003097028A1 Use of edg receptor binding agents in cancer
11/27/2003WO2003097027A1 OIL-IN-WATER EMULSION OF l-MENTHOL
11/27/2003WO2003097026A1 Smooth muscle peristole inhibitor
11/27/2003WO2003097024A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003WO2003096974A2 ORIENTIA TSUTSUGAMUSHI TRUNCATED RECOMBINANT OUTER MENBRANE PROTEIN (r47) AND (r56) VACCINES DIAGNOSTICS AND THERAPEUTICS FOR SCRUB TYPHUS AND HIV INFECTION
11/27/2003WO2003096973A2 A direct cellular energy delivery system
11/27/2003WO2003096965A2 Use of quinoline derivatives with anti-integrase effect and applications thereof
11/27/2003WO2003096782A2 Process for preparing maytansinol
11/27/2003WO2003078361B1 Controlling chemical reactions by spectral chemistry and spectral conditioning
11/27/2003WO2003076469A3 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
11/27/2003WO2003070765A3 Growth hormone fusion protein
11/27/2003WO2003069302A3 Alpha-substituted arylalkyl phosphonate derivatives
11/27/2003WO2003066807A9 Method of inhibiting pathogenicity of infectious agents
11/27/2003WO2003066661A3 Human dr4 antibodies and uses thereof
11/27/2003WO2003065983A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003062268A3 Corticotropin releasing factor receptor 2 agonists
11/27/2003WO2003059942A9 Peptides and peptidomimetics having anti-proliferative activity and their use
11/27/2003WO2003059378A3 Combined use of a glp-1 compound and another drug for treating dyslipidemia
11/27/2003WO2003059270A3 Method for reducing morbidity and mortality in critically ill patients
11/27/2003WO2003057837A3 Methods for using anti-muc18 antibodies
11/27/2003WO2003056899A3 Nitric oxide donors for treatment of disease and injury
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003051383A3 Use of hmgb proteins and nucleic acids that code therefor
11/27/2003WO2003047417A3 Ep4 receptor agonist, compositions and methods thereof
11/27/2003WO2003046150A3 Glycoprotein remodeling using endoglycanases
11/27/2003WO2003042344A3 Apo2 ligand/trail formulations
11/27/2003WO2003040119A8 Angiogenesis inhibitors
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003037338A3 Modulators of the cholesterol biosynthetic pathway
11/27/2003WO2003035883A3 Methods and compositions for inducing tumor-specific cytotoxicity
11/27/2003WO2003032965A3 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003029463A3 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
11/27/2003WO2003029276A3 Copolymers for suppression of autoimmune diseases, and methods of use
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003022209A3 Crystalline forms of valacyclovir hydrochloride
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003014144A3 Molecule
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003009850A1 Substituted piperazines as modulators of the melanocortin receptor
11/27/2003WO2003009817A3 Stable lyophilized pharmaceutical formulation of igg antibodies
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003006611A3 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
11/27/2003WO2003006425A3 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
11/27/2003WO2002099059A3 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002079170A3 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
11/27/2003WO2002072020A3 Novel anti-adhesive compounds and uses thereof
11/27/2003WO2002064791A3 Proteins and nucleic acids encoding same
11/27/2003WO2002060950B1 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2002048368A3 Proteins associated with cell growth, differentiation, and death
11/27/2003WO2001078727A8 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
11/27/2003WO2000062735A3 Treatment of neoplasms with viruses
11/27/2003WO2000050046A8 Stabilized oral pharmaceutical composition containing iodide and iodate and method
11/27/2003US20030221209 Modified proteinase inhibitors
11/27/2003US20030221205 Olfactory and pheromones G-protein coupled receptors
11/27/2003US20030221199 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
11/27/2003US20030220496 3-(optionally hydroxyl)-4-(cyclopropylcarbonyl)-cumene intermediate
11/27/2003US20030220494 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/27/2003US20030220480 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
11/27/2003US20030220472 Treatment of hematopoietic cell deficiencies, stimulating the production of hematopoietic cells, recombinant DNA sequence encodes or vector expression of the muteins; side effect reduction
11/27/2003US20030220405 DNA encoding an epsilon, epsilon-lycopene cyclase from romaine lettuce
11/27/2003US20030220392 Prophylaxis of bacterial infections by administering 2'-(6-Chloropiperonyl)-3-(2,6-dichlorobenzyloxy)cinnamic acid and/or racemic mixtures, as antibiotics
11/27/2003US20030220388 Indoline derivatives
11/27/2003US20030220387 Nitrogen compounds such as 3,9-Difluoro-12,13-dihydro-13-((3,6 -anhydro)-beta-D- glucopyranosyl)-5H-indolo(2,3-a)pyrrolo(3,4 -c)carbazole-5,7(6H)-dione, used as topoisomerase inhibitors, antiproliferative or antitumor agents
11/27/2003US20030220385 Nitrogen compounds such as 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole, administered as phosphodiesterases inhibitors for prophylaxis of cardiovascular or sexual disorders, or as hypotensive agents
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220379 Fermentative preparation process for and crystal forms of cytostatics
11/27/2003US20030220373 Therapeutic uses of PPAR mediators
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220354 Quinazoline ditosylate salt compounds
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220349 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists
11/27/2003US20030220348 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands
11/27/2003US20030220347 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220342 Use of such compounds as corticotropin releasing factor receptor antagonists in the treatment of various neurological disorders
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220331 6-Azauracil derivatives as IL-5 inhibitors
11/27/2003US20030220326 Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220324 Substituted piperazines and methods of use
11/27/2003US20030220323 Such as (2-(4-(2-(1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy)-1-phenyl-ethyl) -piperazin-1-yl)-ethoxy)-acetic acid; for prevention and/or treatment of conditions associated with pathogical levels of substance P
11/27/2003US20030220321 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal
11/27/2003US20030220320 Ningalin b analogs employable for reversing multidrug resistance
11/27/2003US20030220319 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220317 Trypsin-like serine protease inhibitors; anticoagulants; side effect reduction
1 ... 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 ... 1564